[Special Stock] Chong Kun Dang, Exclusive Domestic Rights for Namodenoson FDA Orphan Drug Designation Application News Up...
Jongkundang is showing strength. This is interpreted as being influenced by the news that its Israeli partner CanFight has applied for Orphan Drug Designation (ODD) for Namodenoson, for which Jongkundang holds the distribution rights.
As of 9:57 AM on the 12th, Jongkundang is trading at 110,300 won, up 3.27% from the previous day.
According to industry sources, CanFight Biopharma, Jongkundang's Israeli partner, has reportedly applied to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation (ODD) for Namodenoson. If designated as an orphan drug by the FDA, various benefits can be obtained.
Hot Picks Today
The Quoted 800,000 Won, the Bill Was 5 Million....
- Tragedy in Luxury Apartment: Woman in Her 20s Found Dead, Suspect Identified
- Blue House: "Jeong Dongyoung’s Remarks Not a Leak of Classified Information" .....
- "You Can Only Have This in Korea": Which National Museum Cafe Menu Is Captivatin...
- "Never Hike Alone as a Woman" "Even Two Are at Risk"... Growing Fear of Crime on...
Meanwhile, Jongkundang signed an exclusive domestic distribution rights contract with CanFight in 2016 for Namodenoson, a new drug for liver cancer and MASH treatment. In 2020, it also acquired domestic patent rights.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
